Unrecognized myocardial scars detected by delayed-enhanced MRI are associated with increased levels of NT-proBNP

Coronary Artery Disease

Volumn 22, Issue 3, 2011, Pages 158-164

  Themudo, Raquel Espregueira ^a,b,d   Lindahl, Bertil ^b   Johansson, Lars ^a,c   Venge, Per ^b   Ahlström, Håkan ^a   Barbier, Charlotte Ebeling ^a   Eggers, Kai M ^b   Lind, Lars ^b   Bjerner, Tomas ^a,d  

^a Section of Radiology   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

Epidemiology; infarction; prognosis; silent; troponin I; viability

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN I;

AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DELAYED ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNRECOGNIZED MYOCARDIUM INFARCTION;

AGED; BIOLOGICAL MARKERS; CICATRIX; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; STROKE VOLUME; TROPONIN I;

EID: 79955069027     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328342c72e     Document Type: Article

References (32)

1. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 1995; 122:96-102.
2. Sheifer SE, Gersh BJ, Yanez ND III, Ades PA, Burke GL, Manolio TA. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 2000; 35:119-126. (Pubitemid 30061269)
3. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100:1992-2002. (Pubitemid 29529292)
4. Amado LC, Gerber BL, Gupta SN, Rettmann DW, Szarf G, Schock R, et al. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol 2004; 44:2383-2389. (Pubitemid 39647614)
5. Barbier CE, Bjerner T, Johansson L, Lind L, Ahlstrom H. Myocardial scars more frequent than expected: magnetic resonance imaging detects potential risk group. J Am Coll Cardiol 2006; 48:765-771. (Pubitemid 44175736)
6. Kaandorp TA, Bax JJ, Lamb HJ, Viergever EP, Boersma E, Poldermans D, et al.Which parameters on magnetic resonance imaging determine Q waves on the electrocardiogram? Am J Cardiol 2005; 95:925-929. (Pubitemid 40487739)
7. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113:2733-2743. (Pubitemid 43947991)
8. Kim HW, Klem I, Shah DJ,Wu E, Meyers SN, Parker MA, et al. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med 2009; 6:e1000057.
9. Wiese S, Breyer T, Dragu A,Wakili R, Burkard T, Schmidt-Schweda S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000; 102:3074-3079.
10. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994. (Pubitemid 26415815)
11. Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner JG, et al.; The Christchurch Cardioendocrine Research Group. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999; 81:114-120. (Pubitemid 29119383)
12. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014-1021.
13. Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003; 89:879-881. (Pubitemid 36920811)
14. Eggers KM, Lagerqvist B, Venge P,Wallentin L, Lindahl B. Prognostic value of biomarkers during and after non-ST segment elevation acute coronary syndrome. J Am Coll Cardiol 2009; 54:357-364.
15. Adams JE III, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993; 88:101-106. (Pubitemid 23195438)
16. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105:1760-1763. (Pubitemid 34408881)
17. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006; 113:1071-1078.
18. Hunold P, Schlosser T, Vogt FM, Eggebrecht H, Schmermund A, Bruder O, et al. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. AJR Am J Roentgenol 2005; 184:1420-1426. (Pubitemid 43821809)
19. Ebeling Barbier C, Bjerner T, Hansen T, Andersson J, Lind L, Hulthe J, et al. Clinically unrecognized myocardial infarction detected at MR imaging may not be associated with atherosclerosis. Radiology 2007; 245:103-110. (Pubitemid 47417793)
20. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107:2786-2792. (Pubitemid 36705987)
21. Grebe O,Paetsch I, Kestler HA, Herkommer B, Schnackenburg B, Hombach V, et al. Optimal acquisition parameters for contrast-enhanced magnetic resonance imaging after chronic myocardial infarction. J Cardiovasc Magn Reson 2003; 5:575-587. (Pubitemid 37420772)
22. Sandstede J, Lipke C, Beer M, Hofmann S, Pabst T, KennW, et al. Age- and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging. Eur Radiol 2000; 10:438-442. (Pubitemid 30145755)
23. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005; 25:2368-2375. (Pubitemid 41552656)
24. Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20 536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007; 49:311-319.
25. Eggers KM, Lagerqvist B, Venge P,Wallentin L, Lindahl B. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation 2007; 116:1907-1914. (Pubitemid 350287086)
26. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-2116. (Pubitemid 351679597)
27. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110:3206-3212 (Pubitemid 39525067)
28. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666-675. (Pubitemid 40239214)
29. Vanderheyden M, Bartunek, Claeys G, Manoharan G, Beckers JF, Ide L. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 2006; 39:640-645. (Pubitemid 44192393)
30. Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, McGill DA, Smith WT. Population-based detection of systolic and diastolic dysfunction with amino terminal pro-B-type natriuretic peptide. Am Heart J 2006; 152:941-948. (Pubitemid 44632943)
31. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921-1929.
32. Bodi V, Sanchis J, Llacer A, Facila L, Nunez J, Pellicer M, et al. Multimarker risk strategy for predicting 1-month and 1-year major events in non-STelevation acute coronary syndromes. Am Heart J 2005; 149:268-274. (Pubitemid 40348533)